Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127376651 | 12737665 | 1 | I | 20160701 | 20160831 | 20160913 | 20160913 | EXP | FR-PFIZER INC-2016412320 | PFIZER | 13.00 | YR | F | Y | 43.00000 | KG | 20160913 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127376651 | 12737665 | 1 | PS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous drip | 2 MG, SINGLE | 71484 | 2 | MG | SOLUTION FOR INJECTION | |||||||
| 127376651 | 12737665 | 2 | SS | HOLOXAN | IFOSFAMIDE | 1 | Intravenous drip | 4200 MG, UNK | 0 | 4200 | MG | ||||||||
| 127376651 | 12737665 | 3 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 28 MG, UNK | 0 | 28 | MG | ||||||||
| 127376651 | 12737665 | 4 | SS | ETOPOSIDE TEVA | ETOPOSIDE | 1 | Intravenous drip | 210 MG, UNK | 0 | 210 | MG | ||||||||
| 127376651 | 12737665 | 5 | SS | METHYLPREDNISOLONE MYLAN /00049602/ | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous drip | 40 MG, UNK | 0 | 40 | MG | ||||||||
| 127376651 | 12737665 | 6 | C | ZOPHREN /00955301/ | ONDANSETRON | 1 | Intravenous (not otherwise specified) | 14 MG, UNK | 0 | 14 | MG | ||||||||
| 127376651 | 12737665 | 7 | C | UROMITEXAN | MESNA | 1 | Intravenous (not otherwise specified) | 5040 MG, UNK | 0 | 5040 | MG | ||||||||
| 127376651 | 12737665 | 8 | C | VOGALENE | METOPIMAZINE | 1 | Intravenous (not otherwise specified) | 39.6 MG, UNK | 0 | 39.6 | MG | ||||||||
| 127376651 | 12737665 | 9 | C | BIONOLYTE 5% | 2 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127376651 | 12737665 | 1 | Ewing's sarcoma |
| 127376651 | 12737665 | 2 | Ewing's sarcoma |
| 127376651 | 12737665 | 3 | Ewing's sarcoma |
| 127376651 | 12737665 | 4 | Ewing's sarcoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127376651 | 12737665 | OT |
| 127376651 | 12737665 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127376651 | 12737665 | Anal inflammation | |
| 127376651 | 12737665 | Decreased appetite | |
| 127376651 | 12737665 | Febrile bone marrow aplasia | |
| 127376651 | 12737665 | Mucosal inflammation | |
| 127376651 | 12737665 | Oral pain |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127376651 | 12737665 | 1 | 20160623 | 20160623 | 0 | |
| 127376651 | 12737665 | 2 | 20160623 | 20160625 | 0 | |
| 127376651 | 12737665 | 3 | 20160623 | 20160625 | 0 | |
| 127376651 | 12737665 | 4 | 20160623 | 20160625 | 0 | |
| 127376651 | 12737665 | 5 | 20160623 | 20160625 | 0 | |
| 127376651 | 12737665 | 6 | 20160623 | 20160625 | 0 | |
| 127376651 | 12737665 | 7 | 20160623 | 20160625 | 0 | |
| 127376651 | 12737665 | 8 | 20160623 | 20160625 | 0 |